Recent Research on Role of p53 Family in Small-Cell Lung Cancer

Cancers, Journal Year: 2025, Volume and Issue: 17(7), P. 1110 - 1110

Published: March 26, 2025

Small-cell lung cancer (SCLC) is a highly aggressive malignancy characterized by rapid proliferation, early metastasis, and frequent recurrence, which contribute to poor prognosis. SCLC defined the near-universal inactivation of key tumor suppressor genes, notably TP53 RB1, play central roles in its pathogenesis resistance therapy. The p53 family proteins, including p53, p63, p73, essential maintaining cellular homeostasis suppression. mutations are almost ubiquitous SCLC, leading dysregulated apoptosis cell cycle control. Moreover, p73 shows potential as compensatory mechanism for loss, while p63 has minimal role this type. In review, we explore molecular functional interplay emphasizing members' distinct yet interconnected suppression, immune modulation, therapy resistance. We highlight emerging therapeutic strategies targeting these pathways, reactivating mutant exploiting synthetic lethality, addressing evasion mechanisms. Furthermore, review underscores urgent need novel, isoform-specific interventions enhance treatment efficacy improve patient outcomes challenging disease.

Language: Английский

The Genetically Predicted Causal Associations Between Circulating 3-Hydroxybutyrate Levels and Malignant Neoplasms: A Pan-cancer Mendelian Randomization Study

Clinical Nutrition, Journal Year: 2024, Volume and Issue: 43(11), P. 137 - 152

Published: Oct. 1, 2024

Language: Английский